Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABRIO prospective follow-up registry for children and young adults receiving CAR T-cell therapy
NL-OMON57230Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Princess Máxima Center for Pediatric Oncology. Started Oct 2025; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NL-OMON57230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57230.